Publikationen, an denen er mitarbeitet Óscar María Beloqui Ruiz (37)

2024

  1. Evaluation of measured and calculated small dense low-density lipoprotein in capillary blood and association with the metabolic syndrome

    Clinica Chimica Acta, Vol. 557

2020

  1. NADPH oxidase overactivity underlies telomere shortening in human atherosclerosis

    International Journal of Molecular Sciences, Vol. 21, Núm. 4

2017

  1. Increased phagocytic NADPH oxidase activity associates with coronary artery calcification in asymptomatic men

    Free Radical Research, Vol. 51, Núm. 4, pp. 389-396

2015

  1. Thioredoxin-1/peroxiredoxin-1 as sensors of oxidative stress mediated by NADPH oxidase activity in atherosclerosis

    Free Radical Biology and Medicine, Vol. 86, pp. 352-361

2014

  1. Association of Phagocytic NADPH Oxidase Activity With Hypertensive Heart Disease: A Role for Cardiotrophin-1?

    Hypertension, Vol. 63, Núm. 3, pp. 468-474

  2. Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis

    Journal of the American Heart Association, Vol. 3, Núm. 4

2013

  1. Association of cardiotrophin-1 with left ventricular systolic properties in asymptomatic hypertensive patients

    Journal of Hypertension, Vol. 31, Núm. 3, pp. 587-594

2012

  1. Two variants in the Fibulin2 gene are associated with lower systolic blood pressure and decreased risk of hypertension

    PLoS ONE, Vol. 7, Núm. 8

2011

  1. Association of the peroxisome proliferator-activated receptor α gene L162V polymorphism with stage C heart failure

    Journal of Hypertension, Vol. 29, Núm. 5, pp. 876-883

  2. Relación entre las fases precoces de la enfermedad renal y el síndrome metabólico

    Revista Espanola de Cardiologia, Vol. 64, Núm. 5, pp. 373-378

  3. The A640G CYBA polymorphism associates with subclinical atherosclerosis in diabetes

    Frontiers in Bioscience - Elite, Vol. 3 E, Núm. 4, pp. 1467-1474

  4. ¿el síndrome metabólico en España necesita más estudios descriptivos o más evidencia de su implicación en prevención secundaria? Respuesta

    Revista Espanola de Cardiologia

2010

  1. Corrigendum to "Preliminary characterisation of the promoter of the human p22phox gene: Identification of a new polymorphism associated with hypertension" [FEBS Lett. 542 (2003) 27-31]

    FEBS Letters

  2. Is leptin involved in phagocytic NADPH oxidase overactivity in obesity? Potential clinical implications

    Journal of Hypertension, Vol. 28, Núm. 9, pp. 1944-1950

  3. Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein Kinase C: Potential clinical implications in hypertension (Hypertension (2009) 54 (744-750))

    Hypertension

  4. Protective effect of the 1742(C/G) polymorphism of human cardiotrophin-1 against left ventricular hypertrophy in essential hypertension

    Journal of Hypertension, Vol. 28, Núm. 11, pp. 2219-2226

  5. The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: Potential implication in hypertension (Clinical Science (2009) 116, (233-240))

    Clinical Science

2009

  1. Insulin resistance determines phagocytic nicotinamide adenine dinucleotide phosphate oxidase overactivation in metabolic syndrome patients

    Journal of Hypertension, Vol. 27, Núm. 7, pp. 1420-1430

  2. Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein kinase C: Potential clinical implications in hypertension

    Hypertension, Vol. 54, Núm. 4, pp. 744-750

  3. The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: Potential implication in hypertension

    Clinical Science, Vol. 116, Núm. 3, pp. 233-240